Enhancement of docetaxel efficacy by zoledronic acid pretreatment in docetaxel-resistant prostate cancer cells (PC-3/R and DU-145/R).

e16105 Background: Docetaxel-based chemotherapy is the only globally approved first-line therapy for hormone refractory prostate cancer. Although docetaxel treatment improves survival, all patients...